News

Aubagio Significantly Lowers Plasma NfL Levels in TERIKIDS Trial

Aubagio (teriflunomide) can significantly reduce plasma neurofilament light chain (pNfL) levels, a biomarker of nerve cell damage, in children and adolescents with relapsing-remitting multiple sclerosis (RRMS). That’s according to a new analysis of data from TERIKIDS (NCT02201108), the Phase 3 trial that supported expanding Aubagio’s indication in…

MS Cognitive Problems Can Ease With Rehab, Mindfulness Training

Two alternative treatments for the cognitive challenges people with multiple sclerosis (MS) can face in daily life — cognitive rehabilitation therapy (CRT) and mindfulness-based cognitive therapy (MBCT) — were found to helpful in a clinical trial. Patients randomized to either treatment approach in the REMIND-MS study had fewer…

LAPIX, FDA Meeting Sets Way for LPX-TI641 Clinical Development

Lapix Therapeutics has met with the U.S. Food and Drug Administration (FDA) to determine how to advance its investigational treatment candidate LPX-TI641 into clinical trials for autoimmune diseases such as multiple sclerosis (MS). The pre-investigational new drug (pre-IND) meeting is usually the first formal one companies seeking to…

Relapsing MS Therapy Briumvi Now Commercially Available in US

TG Therapeutics’ Briumvi (ublituximab-xiiy), a CD20 inhibitor recently approved for adults with relapsing forms of multiple sclerosis (MS), is now commercially available in the U.S., the company announced. The treatment was approved in the U.S. late last year, with indications that include clinically isolated syndrome, relapsing-remitting MS (RRMS),…

Fewer Women With MS Choosing to Stop DMT Use While Pregnant

The use of disease-modifying therapies (DMTs) by pregnant women with multiple sclerosis (MS) significantly increased over the last decade or so, and fewer of them are stopping treatment before giving birth, a single-center study in Italy reported. While most patients (95.1%) discontinued a DMT while pregnant between 2005…

Ocrevus Limits Progression Equally in Black, White People With RRMS

Ocrevus (ocrelizumab) seems to be equally effective at stabilizing disease activity in Black and white patients with relapsing-remitting multiple sclerosis (RRMS), a U.S. study found. Disability levels and MRI disease markers remained generally unchanged over the two-year study in both groups, despite Black patients having more severe disability…

Better Standards Needed for NICE Evaluation of MS Treatments: Study

In evaluating potential treatments for multiple sclerosis (MS) over the past two decades, England’s National Institute for Health and Care Excellence (NICE) made differing assumptions about whether and how the therapies’ effects will diminish over time. Such assumptions have a significant impact in estimating a therapy’s cost-effectiveness — a…

Key Myelin Protein Shows Promise as Biomarker for MS

The tiny sacs of cellular content that are released by oligodendrocytes — the myelin-producing cells of the brain and spinal cord — may be good biomarkers for the diagnosis and prognosis of multiple sclerosis (MS) patients, a new study has found. The research showed that levels of myelin basic…

NMSS Names New Jersey Facility Center for Comprehensive MS Care

The National Multiple Sclerosis Society‘s (NMSS) Partners in MS Care program has designated the multiple sclerosis center at Hackensack Meridian Jersey Shore University Medical Center as a Center for Comprehensive MS Care. With the designation, New Jersey now has two Comprehensive MS Care centers serving multiple sclerosis…

Smoking Linked to Depression and Anxiety in MS: Review Study

Smoking tobacco products is associated with a higher prevalence of depression and anxiety among multiple sclerosis (MS) patients, according to a recent systematic review. Across the evaluated studies, current smoking was linked to a 1.3–2.3 times higher prevalence of depression, and about a 1.2 times higher rate of anxiety.

Brain Circuit Associated With MS-related Depression Identified

Researchers have identified specific areas of brain damage associated with depression in multiple sclerosis (MS), but not with other symptoms of the disease. The findings could pave the way toward new treatments for MS-related depression that work to stimulate these regions. “The more we know about the connectivity of…

Use of Virtual Reality Physiotherapy in MS Found to Boost Adherence

Uses of virtual reality-based physiotherapy to improve balance and gait in people with multiple sclerosis (MS) are linked to lower dropout rates than those found with conventional rehabilitation methods, a review of clinical trials suggested. Although the difference between the two physiotherapy approaches was not statistically significant, adherence to…

Exosome-based Therapy Eases Disease in MS Mouse Model

A new therapy that delivers an anti-inflammatory compound to nervous system immune cells via cellular “shipping containers” called exosomes showed promise in a mouse model of multiple sclerosis (MS), a study reports. The study, “Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia,” was published in the…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here